Alogliptin is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, developed by Syrrx, a company which was acquired by Takeda Pharmaceutical Company in 2005. Like other medications for the treatment of Type 2 diabetes, alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.
Alogliptin benzoate(SYR 322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.
DPP-4 Inhibitor Related Products:
Sitagliptin phosphate monohydrate; Linagliptin; Vildagliptin; Saxagliptin; Trelagliptin succinate; Omarigliptin; Teneligliptin hydrobromide; Saxagliptin hydrate; Trelagliptin; Saxagliptin HCL; Alogliptin